AstraZeneca Steps Up, Novo’s Pill Clears Europe
Week Of July 11 – July 17, 2026
AstraZeneca activated five Phase 3 trials for its oral GLP-1 elecoglipron in a single week, adding roughly 1,200 clinical sites and a head-to-head against semaglutide. In the Trial Spotlight, I break down the Embold obesity master protocol and the dapagliflozin-anchored Eluminate diabetes program, and what the design says about how AstraZeneca intends to compete. The Mechanism Explained goes beyond incretins to urocortin-2 and the CRHR2 receptor, a non-incretin pathway aimed at cutting fat while sparing muscle, as Gubra’s GUB-UCN2 enters first-in-human testing. Also this week: the European Commission approves Novo’s Wegovy pill as the first oral GLP-1 for weight management in the EU, and Boehringer’s triple agonist BI 3034701 moves into Phase 2.
A quick programming note: The public GLP-1 Weekly Updates page now carries the recurring trial, regulatory, results, and news roundup. This newsletter is shifting to a less frequent, more focused cadence: source-backed looks at developments where bringing the relevant trials, results, and context together is especially useful. If you want a weekly view of what changed, read GLP-1 Weekly Updates. If you want focused data and context around selected developments, stay subscribed here.
🔥 THIS WEEK’S KEY DEVELOPMENTS
European Commission approves Novo Nordisk’s Wegovy pill for weight management
Novo Nordisk announced that the European Commission (EC) has approved its Wegovy pill (once-daily oral semaglutide 25 mg) for adults with obesity or overweight, making it the first oral GLP-1 for weight management in the EU. The approval was based on the OASIS 4 trial, which showed the pill demonstrated a 17% mean weight loss compared to 3% with placebo. The EC also approved a higher dose Wegovy 7.2 mg injection in a single-dose pen, which delivers 21% weight loss. Both the 17% and 21% figures reflect Novo’s trial product estimand, the effect expected if all participants had adhered to treatment.
Press | Trials: NCT05564117 | Mechanism: GLP-1
Boehringer Ingelheim initiates Phase 2 trial for triple agonist BI 3034701
Boehringer Ingelheim has initiated a Phase II clinical trial (NCT07662122) to evaluate the efficacy and safety of its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in people with obesity and overweight. The company stated that the program advanced into this next phase of development after Phase I studies demonstrated a generally favorable safety and tolerability profile.
Press | Trials: NCT07662122 | Mechanism: GLP-1/GIP/NPY2 triple agonist
💡 TRIAL SPOTLIGHT
Educational spotlight selected by editors
AstraZeneca’s Oral GLP-1 Enters the Ring: Inside the Elecoglipron Phase 3 Program
After remaining a relatively quiet contender in the oral incretin space, AstraZeneca has activated five global Phase 3 trials in a single week for elecoglipron, an oral, small-molecule GLP-1 receptor agonist originally licensed from Eccogene. As a G-protein biased agonist, the drug differentiates itself mechanically by signaling through the cAMP pathway without recruiting beta-arrestin-2 or driving receptor internalization. The massive clinical strategy advances obesity and type 2 diabetes indications in parallel, led by the Embold master protocol for weight management which aims to enroll roughly 4,500 participants ahead of a July 2028 primary completion target. Alongside Embold, the Eluminate diabetes program is now recruiting nearly 5,000 patients across four studies, notably featuring a direct head-to-head comparison against semaglutide in Eluminate-2 and multiple arms exploring combinations with the SGLT2 inhibitor dapagliflozin. By rapidly deploying roughly 1,200 new clinical sites and anchoring its trials around integrated cardiometabolic regimens rather than isolated obesity outcomes, AstraZeneca is signaling a clear strategic intent to aggressively challenge late-stage oral competitors like Lilly’s orforglipron and Novo Nordisk’s oral semaglutide.
ClinicalTrials.gov: NCT07667803 (Embold, Phase 3 obesity master protocol) | NCT07662213 (Eluminate-2, vs semaglutide) | NCT07662109 (Eluminate-5, + dapagliflozin) | NCT07662044 (Eluminate-1) | NCT07662135 (Eluminate-4, renal impairment)
🔬 MECHANISM EXPLAINED
Understanding the science behind the therapeutics
Beyond Incretins: The Urocortin-CRHR2 Pathway and the Muscle-Sparing Bet (Example drug: GUB-UCN2)
With Gubra A/S recently advancing its long-acting urocortin-2 analogue GUB-UCN2 into first-in-human testing across healthy, obese, and type 2 diabetes participants, the corticotropin-releasing hormone receptor 2 (CRHR2) pathway is emerging as a novel non-incretin approach to obesity. Unlike incretin therapies that primarily drive weight loss through central appetite suppression, urocortin-2 is an endogenous peptide of the corticotropin-releasing factor (CRF) family that selectively activates CRHR2, a receptor notably expressed in skeletal muscle, the heart, and the gastrointestinal tract. Activating this pathway increases systemic energy expenditure and enhances glucose uptake directly in skeletal muscle, aiming to drive fat loss while actively preserving or increasing lean mass. This distinct mechanism contrasts sharply with other muscle-preservation strategies like amylin analogues, which still work heavily through satiety signaling, and myostatin pathway inhibitors like bimagrumab, because CRHR2 utilizes a stress-peptide system to modulate energy metabolism directly at the tissue level. While the ability to counteract the lean mass liability of high-efficacy GLP-1 drugs makes this a compelling concept for future add-on or standalone therapy, CRHR2 agonism remains in its earliest clinical stages and must still prove its physiological translation in humans.
🆕 NEWLY REGISTERED TRIALS (5 in last week)
UBT251 Phase 1 drug-drug interaction study evaluating its effects on midazolam, caffeine, and warfarin in participants with excess body weight (Novo Nordisk, n=44)
[Safety/Tolerability]
Trials: NCT07710768 | Mechanism: Triple GLP-1/GIP/glucagon agonist
UBT251 Phase 1 studying its interaction with oral contraceptives and effect on gastric emptying in women with excess body weight (Novo Nordisk, n=40)
[Safety/Tolerability]
Trials: NCT07710729 | Mechanism: Triple GLP-1/GIP/glucagon agonist
Ribupatide Phase 3 trial evaluating its effect on participants with both obesity and knee osteoarthritis (Fujian Shengdi Pharmaceutical, n=382)
[Weight Loss/Efficacy]
Trials: NCT07709910 | Mechanism: Dual GLP-1/GIP agonist
GUB-UCN2 Phase 1/2 first-in-human trial assessing safety and tolerability in healthy lean, obese, and T2D participants (Gubra A/S, n=188)
[Weight Loss/Efficacy | Safety/Tolerability]
Trials: NCT07702890 | Mechanism: CRHR2 agonist (urocortin-2 analogue)
Eloralintide Phase 1 study assessing the safety and tolerability of the new drug in healthy participants (Eli Lilly, n=58)
[Safety/Tolerability]
Trials: NCT07701083 | Mechanism: Amylin receptor agonist
Keep up with the weekly changes
GLP-1 Weekly Updates brings together the latest trial changes, results, regulatory events, and industry news each week.
This newsletter compiles publicly available information from press releases, news sources, and trial registries. Not investment advice.
Get in touch: Reply to this email, leave a comment on the post, or find me on X @GLP1observer. Explore the GLP-1 dashboard at glp1.bio1up.com, browse the GLP-1 Field Guides for explainers on each mechanism class, or see the GLP-1 Verdict, the obesity-drug scoreboard.